Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- OncoTherapy Confirms Safety of Cancer Vaccine OCV-105 in PI Trial
December 6, 2011
- Eisai’s US Research Subsidiary Starts Full Operation
December 5, 2011
- Pfizer, MSD Issue Repeated Warnings for Improper Use of Pneumococcal Vaccines Prevnar, Pneumovax
December 5, 2011
- Teijin Pharma Gets Good Response for Feburic from Medical Institutions: President Arao
December 2, 2011
- Pfizer President Umeda Says Steady Performance for Lyrica, “Business Objectives Achieved”
December 2, 2011
- Bayer, Regeneron Initiate PIII Trial for VEGF Trap-Eye in China
December 2, 2011
- Takeda Announces Overflow of Contaminated Water at Shonan Research Center
December 2, 2011
- Nippon Shinyaku to Open Representative Office in Beijing
December 2, 2011
- DSP, Yoshitomiyakuhin to Terminate Copromotion Agreement for Antipsychotics Lonasen, Lullan
December 2, 2011
- Confusion Seen Temporarily Over FDA Approval for Lipitor Generic
December 2, 2011
- Generic Drug Makers to Continue Launching Generics of Major Drugs Even with 60% Rule
December 2, 2011
- Teva Receives Tentative Approval for Generic Lipitor in the US
December 2, 2011
- Fuji-Keizai Sees Domestic Biopharamaceutical Market Reaching Nearly ¥1 Trillion in 2015
December 1, 2011
- UK AstraZeneca CEO Brennan Says Investment in Japan, a “Very Important Market,” Will Continue
December 1, 2011
- Sandoz Files Application for Additional Indication, Dosage, Administration for Anticancer Drug Paclitaxel Based on Data in Public Domain
December 1, 2011
- I'rom HD Sells All I'rom Pharmaceutical Shares to Kyowa Pharmaceutical Industry
December 1, 2011
- DSP Files NDA for Fixed-Dose Combination of ARB Avapro (Irbesartan) / CCB Amlodin (Amlodipine)
December 1, 2011
- Hamari Chemicals Announces New San Diego Research Center
December 1, 2011
- Takeda Announces Overflow of Contaminated Water at Shonan Research Center
December 1, 2011
- Ranbaxy Launches Generic Lipitor; Marketing Tie-up with Teva
December 1, 2011
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…